Sven Weiler joins Endogena as VP Medicinal Chemistry

We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022. “I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company […]

Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa

Zürich, Switzerland and Toronto, Canada; 12th July 2022 Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of […]